Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Update

Lonza Group Ag (OTCMKTS:LZAGY) was the recipient of a significant growth in short interest in April. As of April 30th, there was short interest totaling 27,348 shares, a growth of 117.6% from the April 15th total of 12,566 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 119,668 shares, the short-interest ratio is currently 0.2 days.

Analyst Ratings Changes

LZAGY has been the topic of a number of analyst reports. Royal Bank Of Canada upgraded shares of Lonza Group from a “hold” rating to a “moderate buy” rating in a research note on Wednesday, February 11th. Zacks Research upgraded shares of Lonza Group from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Lonza Group presently has a consensus rating of “Moderate Buy”.

Lonza Group Stock Down 2.0%

Shares of LZAGY traded down $1.21 during mid-day trading on Friday, reaching $59.51. The company had a trading volume of 116,004 shares, compared to its average volume of 72,297. The company’s 50 day simple moving average is $63.07 and its 200 day simple moving average is $66.30. Lonza Group has a 1-year low of $58.53 and a 1-year high of $73.85. The company has a current ratio of 2.24, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42.

About Lonza Group

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.